COMP <GO>
WST vs MDLN // EV/EBITDA & P/E VALUATION
West Pharmaceutical Services Inc. (NYSE) VS. Medline Inc. (NASDAQ) • 15-METRIC TALLY: WST 6
— MDLN 6
▲ EV/EBITDA & P/E VALUATION LEADER: MDLN
LAST: $412.62 (-0.97%) • MKT CAP: $29.32B
valuation
34.7x
LAST: $32.12 (+0.38%) • MKT CAP: $42.07B
valuation
20.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (WST VS. MDLN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | WST | MDLN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 35.90% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.90% | 8.20% | +9.70 | WST | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 34.7x | 20.3x | +14.40 | MDLN | /valuation <GO> |
| Free Cash Flow Yield | 1.60% | 3.08% | -1.48 | MDLN | /fcf-yield <GO> |
| Operating Margin | 19.00% | 7.80% | +11.20 | WST | /operating-margins <GO> |
| Net Profit Margin | 16.10% | 68.00% | -51.90 | MDLN | /net-margins <GO> |
| Revenue Growth (YoY) | 6.30% | 11.50% | -5.20 | MDLN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.21% | 0.00% | +0.21 | WST | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 19.06 | 2.50 | +16.56 | WST | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 5/9 | +4.00 | WST | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 77.0 | 30.9 | +46.10 | WST | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.11 | -0.03 | MDLN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 55.2x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $29.32B | $42.07B | -$12.75B | MDLN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | WST REV | MDLN REV | WST GROSS % | MDLN GROSS % | WST FCF | MDLN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.07B | $28.43B | 35.9% | 26.4% | $468.9M | $1.30B |
| FY 2024 | $2.89B | $25.51B | 34.5% | 27.3% | $276.4M | $1.42B |
| FY 2023 | $2.95B | $23.23B | — | — | $643.8M | $639.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
WST // BETA 1.08
MDLN // BETA 1.11